OncoMatch/Clinical Trials/NCT06051240
Lithium Treatment to Prevent Cognitive Impairment After Brain Radiotherapy
Is NCT06051240 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Lithium for cognitive impairment.
Treatment: Lithium — Randomized, placebo-controlled, double-blinded, parallel group clinical trial to investigate if 6 months of oral lithium tablets (S-lithium 0,5-1,0 mmol/l) will prevent cognitive decline after brain radiotherapy in pediatric brain tumor survivors. Primary outcome measure is Processing Speed Index (PSI) 2 years after start of study treatment.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Glioblastoma
Demographics
Prior therapy
Must have received: radiation therapy — cranial/craniospinal
Lab requirements
Kidney function
cystatin c derived glomerular filtration rate >= 60
Cardiac function
no cardiac failure or heart disease, including brugada syndrome (or family history thereof)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06051240 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received radiation therapy.
Is there an age limit?
Yes. Patients must be 17 years or younger and at least 5 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages